CJC-1295 and Ipamorelin, Two Accelerators in One Vial

This is the combination patients ask me about more than any other peptide, usually after a friend at the gym started it, and it arrives in one vial with two molecules and a confident story attached. The pharmacology underneath is real, which is why the story sells. What's missing is the part where somebody ran the trial.

Growth hormone leaves the pituitary in pulses, driven by a hypothalamic peptide called growth hormone releasing hormone and answered by IGF-1 from the liver. I covered that axis, its brake, and its decline with age in my post on sermorelin.

Two accelerators, pressed together

The pituitary has two separate gas pedals for growth hormone release, the GHRH receptor and the ghrelin receptor, and this blend presses both. CJC-1295 handles the first as a modified GHRH(1-29), and ipamorelin handles the second as a ghrelin-receptor agonist. Pairing them is meant to produce a larger burst than either molecule alone, which is the rationale for selling them together.

What CJC-1295 is, and a detail that gets glossed over

CJC-1295 is GHRH(1-29) with a chemical arm added that latches permanently onto albumin, the most abundant protein in your blood, so that the peptide circulates for days instead of minutes. Jetté and colleagues built several of these conjugates and tested them in rats, identifying CJC-1295 as the version that bound the free thiol on albumin, produced four times the growth hormone output of plain GHRH(1-29) over two hours, and remained detectable in plasma beyond 72 hours [1]. That albumin-binding arm is called a drug affinity complex, and it's the whole reason the molecule lasts.

Much of the compounded material sold as CJC-1295 omits the drug affinity complex, a version often labeled CJC-1295 without DAC or modified GRF(1-29), which behaves like ordinary sermorelin with a half-life of minutes rather than days. Every piece of published human data below comes from the long-acting, albumin-binding form. If your vial says no DAC, the pharmacology described in those papers doesn't apply to what's in your hand.

The human pharmacology

Teichman and colleagues ran two randomized, placebo-controlled ascending-dose trials of CJC-1295 in healthy adults aged 21 to 61. A single subcutaneous injection raised mean growth hormone 2-fold to 10-fold for 6 days or more and IGF-1 1.5-fold to 3-fold for 9 to 11 days. The estimated half-life ran 5.8 to 8.1 days, and IGF-1 stayed above baseline for up to 28 days after repeated dosing [2]. No serious adverse reactions were reported, with the 30 and 60 microgram per kilogram doses best tolerated [2].

What matters more is what constant GHRH stimulation does to the pulses. Ionescu and Frohman sampled blood every 20 minutes overnight in healthy young men before and a week after a single injection, and found that pulse frequency and pulse size were unchanged while trough growth hormone levels rose 7.5-fold, lifting mean growth hormone by 46 percent and IGF-1 by 45 percent [3]. Pulsatility survived, which supports the argument that a secretagogue keeps the system's own rhythm, though my read is that the 7.5-fold rise in the troughs deserves more attention than it gets, since the natural pattern includes long stretches of near-zero growth hormone and a week-long molecule fills those valleys in.

What ipamorelin is

Ipamorelin is a five-amino-acid peptide that activates the ghrelin receptor, the same receptor the hunger hormone from your stomach uses, and it was designed at Novo Nordisk to do that one job cleanly. Raun and colleagues, describing it in 1998, showed that ipamorelin released growth hormone in rat pituitary cells, anesthetized rats, and conscious swine with potency comparable to the older peptide GHRP-6. Unlike GHRP-6 and GHRP-2, it produced no rise in ACTH or cortisol even at doses more than 200 times those needed for growth hormone release, and it left prolactin, LH, FSH, and TSH alone [4]. That selectivity is the reason this particular ghrelin agonist ended up in compounded blends rather than one of its cruder predecessors.

The human pharmacokinetic work is thin but real. Gobburu and colleagues infused five ascending doses into groups of eight healthy men each and found dose-proportional kinetics with a terminal half-life of about 2 hours, and each dose produced a single episode of growth hormone release peaking around 40 minutes and falling back to negligible levels [5]. Ipamorelin gives one clean pulse and then leaves, which is why it's paired with something long-acting.

The trials that were run, and what they showed

Ipamorelin did reach a randomized phase 2 trial, though not for anything related to aging. Beck and colleagues gave 0.03 mg per kilogram intravenously twice daily to patients recovering from bowel resection, to test whether it would speed the return of gut motility after surgery, and across 114 patients the median time to tolerating a solid meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, a difference that didn't reach significance [6]. The drug was well tolerated and it didn't work for that indication, which matters because it's the only controlled trial of ipamorelin in patients.

The animal work covers bone and body weight. Svensson and colleagues gave ipamorelin or GHRP-6 continuously to adult female rats for 12 weeks and found higher bone mineral content and larger bone dimensions, though the volumetric bone mineral density, the amount of mineral packed into a given volume of bone, didn't change [7]. The bones grew bigger rather than denser, which isn't what someone hoping to treat osteoporosis wants.

What nobody has tested

No published trial has tested CJC-1295 and ipamorelin together in humans. No trial of either molecule has shown improved body composition, strength, physical function, or any longevity outcome in healthy adults. What exists is pharmacology, meaning we know these peptides raise growth hormone and IGF-1 in people, and the clinical case is an extrapolation from that to benefits nobody has measured.

The closest long-term human evidence comes from a different ghrelin-receptor drug. Nass and colleagues randomized 65 healthy adults aged 60 to 81 to the oral ghrelin mimetic MK-677 or placebo for a year, and growth hormone and IGF-1 rose into the young-adult range while fat-free mass increased 1.1 kg against a 0.5 kg loss on placebo [8]. Abdominal visceral fat didn't change, limb fat rose more in the treated group, body weight climbed 2.7 kg, fasting glucose rose about 5 mg per deciliter with reduced insulin sensitivity, and the extra fat-free mass produced no improvement in strength or function [8]. That last finding is the one I keep coming back to, since gaining lean tissue that doesn't make you stronger isn't the outcome anyone is paying for.

Risks, and who shouldn't use this

The predictable effects of pushing growth hormone upward are fluid retention, joint aches, numbness and tingling in the hands, and a drift upward in glucose with reduced insulin sensitivity, all of which appeared in the year-long ghrelin mimetic trial above [8]. Raising IGF-1 carries the same theoretical cancer concern I laid out in the sermorelin post, so we don't offer this to anyone with an active malignancy, and it has no role in pregnancy. The compounded blend isn't FDA-approved, and neither molecule has ever held FDA approval, unlike the related tesamorelin, which is approved as Egrifta.

Competitive athletes should stay away entirely, since growth hormone releasing peptides including ipamorelin appear on the World Anti-Doping Agency prohibited list, and anti-doping laboratories have developed urine assays for their metabolites [9]. Synthetic GHRH analogs including CJC-1295 are prohibited as well, with detection methods validated down to about 1 nanogram per milliliter [10].

How we think about it

Anyone considering this blend should start by fixing what suppresses their own growth hormone output, since the pulses that matter most arrive during deep sleep and the physiology of that is worth understanding first. Resistance training, enough protein, and getting visceral fat and fasting insulin down do more for lean mass than any secretagogue has been shown to do, and they carry decades of trial evidence instead of an extrapolation.

If someone still wants to try it after hearing all of that, we check IGF-1 and glucose before and during, we treat rising fasting glucose or an IGF-1 above the age-adjusted range as a reason to stop, and we're clear that we're acting on pharmacology rather than proven outcomes. I'd rather say that plainly than pretend the trial exists.

Ask a provider about CJC-1295 + ipamorelin

References

1. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID: 15817669
2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID: 16352683
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID: 17018654
4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822
5. Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PMID: 10496658
6. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PMID: 25331030
7. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000. PMID: 10828840
8. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PMID: 18981485
9. Semenistaya E, Zvereva I, Thomas A, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015. PMID: 25869809
10. Memdouh S, Gavrilović I, Ng K, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. PMID: 34665524